European Commission Approved its First JAK Inhibitor to Treat Atopic Dermatitis
The company ‘AbbVie’ announced that, the European Commission has approved RINVOQ, an oral, selective and reversible JAK inhibitor, used for the treatment of the moderate to severe atopic dermatitis in the adolescents of 12 years and above and adults, who have been the candidate for the systematic therapy of the disease. According to the company, […]
Continue Reading